Please login to the form below

Not currently logged in
Email:
Password:

Dr Paula Salmikangas joins NDA Group

Moves to the regulatory affairs consultancy from the Finnish Medicines Agency

Paula SalmikaUK-headquartered regulatory affairs consultancy the NDA Group has appointed Dr Paula Salmikangas as a director.

She is the former chair of the EMA’s Committee for Advanced Therapies and comes to NDA from the Finnish Medicines Agency, where she served as a research professor.

She has also served as an adjunct professor of biochemistry for the University of Helsinki since 2006.

Dr Werner Van den Eynde, VP of NDA’s Advisory Board, said: “I am very excited to welcome Dr Paula Salmikangas on board. With her experience in and in-depth knowledge of biopharmaceuticals and advanced therapies she will be able to add tremendous value to clients in these areas and help them to make new and promising medicines available to patients.”

Dr Salmikangas is the second recent senior appointment at NDA Group following the appointment of Dr Van den Eynde, who joined earlier this month as its new vice president.

25th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics